Newbury Pharmaceuticals

Lapatinib Newbury approved by the Swedish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lapatinib Newbury 250 mg film-coated tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews.

Lapatinib is a targeted cancer drug, also known by its brand name Tyverb, that is used to treat certain types of breast cancer, where tumors overexpress HER2.

“Lapatinib is a terrific addition to the existing high-value oncology product portfolio, and we are proud to further strengthen our commitment within oncology. Based on this positive progress, we will proceed to launch this product, within respective markets as soon as regulatory exclusivities and patents allow us.” says Mr Lars Minor CEO of Newbury.

Newbury currently has licensed ten (10) products within oncology and plan to offer treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer and thyroid cancer).

Datum 2023-03-24, kl 11:45
Källa MFN
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.
Copy Trading innebär inte investeringsrådgivning. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.